Nektar Therapeutics
(NASDAQ : NKTR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading NKTR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-3.48%80.471.8%$677.67m
BIIBBiogen Inc.
-4.02%229.021.0%$525.14m
CELGCelgene Corporation
-4.34%96.291.2%$438.11m
AMGNAmgen Inc.
-3.82%146.451.0%$388.51m
ANACAnacor Pharmaceuticals, Inc.
-0.14%99.0615.2%$320.35m
REGNRegeneron Pharmaceuticals, Inc.
-4.95%339.483.1%$301.85m
ALXNAlexion Pharmaceuticals, Inc.
-8.56%112.992.5%$274.13m
ILMNIllumina, Inc.
-5.24%138.914.9%$155.27m
VRTXVertex Pharmaceuticals Incorporated
-7.14%81.902.6%$124.14m
MDVNMedivation, Inc.
-3.90%56.952.8%$120.74m
BMRNBioMarin Pharmaceutical Inc.
-7.94%77.014.0%$117.35m
SRPTSarepta Therapeutics, Inc.
3.58%18.5249.4%$116.18m
CPXXCelator Pharmaceuticals, Inc.
0.13%30.198.5%$107.30m
AAgilent Technologies, Inc.
-5.48%44.121.0%$94.74m
IONSIonis Pharmaceuticals, Inc.
-6.91%21.978.6%$94.46m

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. The company provides small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.